For outpatient CAP with no risk of Pseudomonas, which regimen is appropriate for empirical therapy?

• A. Levofloxacin
• B. Amoxicillin with azithromycin or doxycycline
• C. Cefuroxime
• D. Aztreonam

Answer: (B)

The main idea here is selecting an empirical treatment for outpatient CAP that covers the typical bacteria (like Streptococcus pneumoniae and Haemophilus influenzae) as well as atypical organisms (such as Mycoplasma and Chlamydophila) in a patient with no risk of Pseudomonas.

Amoxicillin plus either azithromycin or doxycycline does exactly that. Amoxicillin targets the common, typical CAP pathogens, while a macrolide (azithromycin) or doxycycline adds reliable coverage against atypicals. This combination gives broad, appropriate empirical coverage for a healthy outpatient without Pseudomonas risk, following common guidelines.

Other regimens fall short for empirical CAP in this scenario. A fluoroquinolone like levofloxacin monotherapy covers both typical and atypicals but is generally reserved to spare broad-spectrum agents and special situations, so it’s not the preferred first-line choice here. Cefuroxime alone lacks adequate coverage of atypical pathogens, which are a notable portion of CAP cases. Aztreonam mainly covers gram-negative bacteria and does not provide the needed coverage for gram-positive organisms like Streptococcus pneumoniae or for atypicals, making it unsuitable as empirical CAP therapy in this context.